This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a phase 2 study of AZD2171 in patients with recurrent glioblastoma. Eligible patients must have archival paraffin-embedded tumor tissue from a prior resection available for analysis. In addition, eligible patients must have a Karnofsky Performance Score (KPS) of 60 or greater, can have received no more than 2 anti-neoplastic drugs as part of their prior treatment, must have contrast-enhancing tumor on MRI, must not have had tumor resection (or other forms of major surgery) within 90 days, must not have received any form of cranial radiation within the past 3 months and must be capable of providing informed consent.Eligible patients will receive AZD2171 at a dose of 45 mg daily by mouth continuously. There is no maximal length of therapy.
Showing the most recent 10 out of 945 publications
